NCT07458191 Apixaban Safety and Therapy Adherence in Patients With Atrial Fibrillation
| NCT ID | NCT07458191 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Bosnalijek D.D |
| Condition | Nonvalvular Atrial Fibrillation |
| Study Type | OBSERVATIONAL |
| Enrollment | 800 participants |
| Start Date | 2025-10-09 |
| Primary Completion | 2027-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 800 participants in total. It began in 2025-10-09 with a primary completion date of 2027-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this observational study is to evaluate safety and therapeutic adherence during anticoagulant prophylaxis with apixaban in patients with nonvalvular atrial fibrillation. The main questions it aims to answer are: * What is the incidence of major bleeding and clinically relevant non-major bleeding during anticoagulant prophylaxis with apixaban in patients with nonvalvular atrial fibrillation? * What is therapy adherence during anticoagulant prophylaxis with apixaban in patients with nonvalvular atrial fibrillation? * What is frequency and types of other adverse reactions, excluding bleeding, during anticoagulant prophylaxis with apixaban in patients with nonvalvular atrial fibrillation? Participants will be followed for six months through four measurements. The first and fourth measurements will be performed in person, while the remaining measurements can also be recorded by telephone, if the patient's condition allows. Any bleeding or serious adverse reactions to the medication being administered will be recorded immediately, through unscheduled measurements. Adverse reactions will be recorded at each measurement. Adherence to the medication being administered will be evaluated using the BARS scale.
Eligibility Criteria
Inclusion Criteria: * Patients over 18 years of age. * Hemodynamically stable patients. * Patients with non-valvular atrial fibrillation. * Patients in whom the investigator, based on clinical assessment makes a decision to introduce apixaban therapy. * Patients who are on apixaban therapy for the first time Exclusion Criteria: * Positive history of angioneurotic edema. * Active, clinically significant bleeding. * Congenital or acquired bleeding disorder. * The presence of a malignant tumor. * Current or recent presence of gastrointestinal ulcer. * The presence of established or suspected esophageal varices. * Positive history of arteriovenous malformations, vascular aneurysms or intraspinal and intracerebral vascular anomalies. * Patients with artificial heart valves. * Liver cirrhosis and active liver disease associated with coagulopathy and clinically significant risk of bleeding. * Dialysis patients (GFR \<15 ml/min). * Simultaneous use of other anticoagulants. * Pregnancy and breastfeeding. * Patients who previously used apixaban in therapy. Withdrawal Criteria: * Deterioration of the clinical picture of the underlying disease that requires discontinuation of investigational therapy. * Development of serious adverse events that require discontinuation of therapy. * Occurrence of pregnancy. * Development of another disease that affects the course of research.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07458191 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Nonvalvular Atrial Fibrillation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07458191 currently recruiting?
Yes, NCT07458191 is actively recruiting participants. Contact the research team at HalimaK@Bosnalijek.ba for enrollment information.
Where is the NCT07458191 trial being conducted?
This trial is being conducted at Sarajevo, Bosnia and Herzegovina.
Who is sponsoring the NCT07458191 clinical trial?
NCT07458191 is sponsored by Bosnalijek D.D. The trial plans to enroll 800 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.